Literature DB >> 34344966

Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.

Shinichi Mizuno1, Rui Yamaguchi2, Takanori Hasegawa3, Shuto Hayashi2, Masashi Fujita4, Fan Zhang5, Youngil Koh6, Su-Yeon Lee7, Sung-Soo Yoon6, Eigo Shimizu2, Mitsuhiro Komura2, Akihiro Fujimoto4, Momoko Nagai8, Mamoru Kato8, Han Liang9, Satoru Miyano2,3, Zemin Zhang10, Hidewaki Nakagawa11, Seiya Imoto12,13.   

Abstract

Immune reactions in the tumor microenvironment are an important hallmark of cancer, and emerging immune therapies have been proven effective against several types of cancers. To investigate cancer genome-immune interactions and the role of immunoediting or immune escape mechanisms in cancer development, we analyzed 2834 whole genome and RNA sequencing datasets across 31 distinct tumor types with respect to key immunogenomic aspects and provided comprehensive immunogenomic profiles of pan-cancers. We found that selective copy number changes in immune-related genes may contribute to immune escape. Furthermore, we developed an index of the immunoediting history of each tumor sample based on the information of mutations in exonic regions and pseudogenes and evaluated the immunoediting history of each tumor. Our immuno-genomic analyses of pan-cancers have the potential to identify a subset of tumors with immunogenicity and diverse backgrounds or intrinsic pathways associated with their immune status and immunoediting history.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34344966     DOI: 10.1038/s41598-021-95287-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  35 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

3.  IMGT, the international ImMunoGeneTics database.

Authors:  M P Lefranc; V Giudicelli; C Ginestoux; J Bodmer; W Müller; R Bontrop; M Lemaitre; A Malik; V Barbié; D Chaume
Journal:  Nucleic Acids Res       Date:  1999-01-01       Impact factor: 16.971

Review 4.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

Review 7.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

Review 8.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

Authors:  Padmanee Sharma; Klaus Wagner; Jedd D Wolchok; James P Allison
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Authors:  Carsten Linnemann; Marit M van Buuren; Laura Bies; Els M E Verdegaal; Remko Schotte; Jorg J A Calis; Sam Behjati; Arno Velds; Henk Hilkmann; Dris El Atmioui; Marten Visser; Michael R Stratton; John B A G Haanen; Hergen Spits; Sjoerd H van der Burg; Ton N M Schumacher
Journal:  Nat Med       Date:  2014-12-22       Impact factor: 53.440

View more
  3 in total

Review 1.  Moving pan-cancer studies from basic research toward the clinic.

Authors:  Feng Chen; Michael C Wendl; Matthew A Wyczalkowski; Matthew H Bailey; Yize Li; Li Ding
Journal:  Nat Cancer       Date:  2021-09-16

2.  PCIG: a web-based application to explore immune-genomics interactions across cancer types.

Authors:  Anna Pedrola; Sebastià Franch-Expósito; Sara Lahoz; Roger Esteban-Fabró; Rodrigo Dienstmann; Laia Bassaganyas; Jordi Camps
Journal:  Bioinformatics       Date:  2022-02-18       Impact factor: 6.931

3.  Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.

Authors:  Shota Sasagawa; Hiroaki Kato; Koji Nagaoka; Changbo Sun; Motohiro Imano; Takao Sato; Todd A Johnson; Masashi Fujita; Kazuhiro Maejima; Yuki Okawa; Kazuhiro Kakimi; Takushi Yasuda; Hidewaki Nakagawa
Journal:  Cell Rep Med       Date:  2022-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.